Patrick James Orme

Array ( [id] => 7656406 [patent_doc_number] => 20110305675 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-15 [patent_title] => 'METHODS FOR EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS' [patent_app_type] => utility [patent_app_number] => 13/145706 [patent_app_country] => US [patent_app_date] => 2010-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 39860 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0305/20110305675.pdf [firstpage_image] =>[orig_patent_app_number] => 13145706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6518803 [patent_doc_number] => 20100203036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-08-12 [patent_title] => 'TARGETS FOR TUMOR GROWTH INHIBITION' [patent_app_type] => utility [patent_app_number] => 12/648436 [patent_app_country] => US [patent_app_date] => 2009-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 49 [patent_no_of_words] => 35271 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0203/20100203036.pdf [firstpage_image] =>[orig_patent_app_number] => 12648436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6113895 [patent_doc_number] => 20110190370 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-04 [patent_title] => 'MODULATION OF HIF1(ALPHA) AND HIF2(ALPHA) EXPRESSION' [patent_app_type] => utility [patent_app_number] => 12/642534 [patent_app_country] => US [patent_app_date] => 2009-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34924 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0190/20110190370.pdf [firstpage_image] =>[orig_patent_app_number] => 12642534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8435561 [patent_doc_number] => 08283330 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-10-09 [patent_title] => 'Modulators of pharmacological agents' [patent_app_type] => utility [patent_app_number] => 12/637467 [patent_app_country] => US [patent_app_date] => 2009-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 45 [patent_no_of_words] => 32380 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12637467 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8410471 [patent_doc_number] => 08273868 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-09-25 [patent_title] => 'Compositions and methods for inhibiting viral replication' [patent_app_type] => utility [patent_app_number] => 12/631689 [patent_app_country] => US [patent_app_date] => 2009-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 10 [patent_no_of_words] => 11656 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12631689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7545450 [patent_doc_number] => 08053422 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-11-08 [patent_title] => 'Anti-cancer oligodeoxynucleotides' [patent_app_type] => utility [patent_app_number] => 12/630315 [patent_app_country] => US [patent_app_date] => 2009-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 14158 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/053/08053422.pdf [firstpage_image] =>[orig_patent_app_number] => 12630315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6186701 [patent_doc_number] => 20110124706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-05-26 [patent_title] => 'SOCS3 Inhibition Promotes CNS Neuron Regeneration' [patent_app_type] => utility [patent_app_number] => 12/626351 [patent_app_country] => US [patent_app_date] => 2009-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4419 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0124/20110124706.pdf [firstpage_image] =>[orig_patent_app_number] => 12626351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7977979 [patent_doc_number] => 08071737 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-12-06 [patent_title] => 'Nucleic acid ligand complexes' [patent_app_type] => utility [patent_app_number] => 12/624314 [patent_app_country] => US [patent_app_date] => 2009-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 36 [patent_no_of_words] => 23247 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/071/08071737.pdf [firstpage_image] =>[orig_patent_app_number] => 12624314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8577915 [patent_doc_number] => 08344125 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-01-01 [patent_title] => 'Modified iRNA agents' [patent_app_type] => utility [patent_app_number] => 12/619382 [patent_app_country] => US [patent_app_date] => 2009-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 12 [patent_no_of_words] => 45812 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12619382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8571227 [patent_doc_number] => 08337868 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-12-25 [patent_title] => 'Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue' [patent_app_type] => utility [patent_app_number] => 12/588368 [patent_app_country] => US [patent_app_date] => 2009-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 12981 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12588368 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10044387 [patent_doc_number] => 09084770 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-07-21 [patent_title] => 'Modulation of insulin like growth factor I receptor expression in cancer' [patent_app_type] => utility [patent_app_number] => 12/578471 [patent_app_country] => US [patent_app_date] => 2009-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 34 [patent_no_of_words] => 25608 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12578471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7535238 [patent_doc_number] => 08048864 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2011-11-01 [patent_title] => 'Regulators of NFAT and/or store-operated calcium entry' [patent_app_type] => utility [patent_app_number] => 12/575655 [patent_app_country] => US [patent_app_date] => 2009-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 40587 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/048/08048864.pdf [firstpage_image] =>[orig_patent_app_number] => 12575655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8103919 [patent_doc_number] => 08153606 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-04-10 [patent_title] => 'Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1' [patent_app_type] => utility [patent_app_number] => 12/573083 [patent_app_country] => US [patent_app_date] => 2009-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 14 [patent_no_of_words] => 28517 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/153/08153606.pdf [firstpage_image] =>[orig_patent_app_number] => 12573083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6307597 [patent_doc_number] => 20100069471 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-03-18 [patent_title] => 'CHEMICALLY MODIFIED OLIGONUCLEOTIDES' [patent_app_type] => utility [patent_app_number] => 12/561529 [patent_app_country] => US [patent_app_date] => 2009-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 59456 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0069/20100069471.pdf [firstpage_image] =>[orig_patent_app_number] => 12561529 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6320125 [patent_doc_number] => 20100113292 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-05-06 [patent_title] => 'METHODS OF OBTAINING ACTIVE ANTISENSE COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 12/557358 [patent_app_country] => US [patent_app_date] => 2009-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 10277 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0113/20100113292.pdf [firstpage_image] =>[orig_patent_app_number] => 12557358 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6024340 [patent_doc_number] => 20110052666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-03-03 [patent_title] => 'Compositions, Methods, and Systems for SIRNA Delivery' [patent_app_type] => utility [patent_app_number] => 12/467720 [patent_app_country] => US [patent_app_date] => 2009-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 6384 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0052/20110052666.pdf [firstpage_image] =>[orig_patent_app_number] => 12467720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6360509 [patent_doc_number] => 20100087508 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-04-08 [patent_title] => 'Compositions and Methods for Inhibiting Expression of Eg5 and VEGF Genes' [patent_app_type] => utility [patent_app_number] => 12/552207 [patent_app_country] => US [patent_app_date] => 2009-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 47239 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0087/20100087508.pdf [firstpage_image] =>[orig_patent_app_number] => 12552207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6102710 [patent_doc_number] => 20110166203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-07 [patent_title] => 'ANTI-HEPATITIS C VIRUS COMPOSITION' [patent_app_type] => utility [patent_app_number] => 13/060474 [patent_app_country] => US [patent_app_date] => 2009-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 7256 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0166/20110166203.pdf [firstpage_image] =>[orig_patent_app_number] => 13060474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7685249 [patent_doc_number] => 20100120892 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-05-13 [patent_title] => 'METHODS AND COMPOSITIONS FOR THE INHIBITION OF STAT5 IN PROSTATE CANCER CELLS' [patent_app_type] => utility [patent_app_number] => 12/548383 [patent_app_country] => US [patent_app_date] => 2009-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 12645 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0120/20100120892.pdf [firstpage_image] =>[orig_patent_app_number] => 12548383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7504077 [patent_doc_number] => 08034922 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-10-11 [patent_title] => 'Compositions and methods for modulating activity of capped small RNAs' [patent_app_type] => utility [patent_app_number] => 12/545729 [patent_app_country] => US [patent_app_date] => 2009-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 7 [patent_no_of_words] => 9753 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/034/08034922.pdf [firstpage_image] =>[orig_patent_app_number] => 12545729 [rel_patent_id] =>[rel_patent_doc_number] =>)